Skip to main content

Bio-Techne Corp Value Stock - Dividend - Research Selection

Bio-techne

ISIN: US09073M1045 , WKN: A12ENG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

2025-09-03
Get insights from Bio-Techne's 2025 conference: market performance, biotech trends, and

Why Bio-Techne (TECH) Shares Are Sliding Today

2025-09-02
Shares of life sciences company Bio-Techne (NASDAQ:TECH) fell 3.3% in the afternoon session after the major indices continued to retreat (Nasdaq -1.5%, S&P 500 -1.2%) amid profit-taking and renewed concerns about tariffs. The decline was not driven by company-specific news but rather widespread negative sentiment as investors returned from the Labor Day holiday. Major U.S. indexes, including the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, all tumbled. The downturn was fueled by

Baird Small/Mid Cap Growth Equity Fund Q2 2025 Commentary

2025-08-28
The Baird Small/Mid Cap Growth strategy increased +4.5% in the second quarter, net of fees. Read more here.

Bio-Techne to Present at Upcoming Investor Conferences

2025-08-27
Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:

Bio-Techne, 10x Genomics, Lumen, EPAM, and ASGN Shares Are Soaring, What You Need To Know

2025-08-22
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested that with inflation risks moderating and unemployment remaining low, the Federal Reserve might consider a shift in its monetary policy stance, including potential interest rate cuts. This outlook eased market concerns about prolonged high interest rates and their impact on economic growth. The prospe

CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls

2025-08-21
CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

2025-08-21

Macquarie Mid Cap Growth Fund Q2 2025 Commentary

2025-08-19
For 2Q2025, Macquarie Mid Cap Growth Fund Institutional Class shares underperformed the Fund’s benchmark, the Russell Midcap Growth Index.

Bio-Techne Stock: Analyst Estimates & Ratings

2025-08-19
Bio-Techne has considerably underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Bruker: Former Academia Customer Strength, Now Incredible Weakness

2025-08-15
Bruker faces challenges amid NIH funding cuts and academic reliance. Short-term risks are high, but investors may benefit from a recovery. See more on BRKR.